This Forum brings together forward-thinking investors and a hand-selected group of high-potential startups for focused, insight-driven presentations.
Each company delivers a 5-minute presentation with Q&A, designed to surface meaningful discussion, validate opportunity, and accelerate engagement.
The program also features updates from select alumni companies, offering a clear view into post-Forum progress, milestones achieved, and future direction.
Where innovation meets traction—and relationships turn into outcomes.
Animate Biosciences pioneers AI-designed, regenerative biology–inspired peptide drugs for chronic inflammation and fibrosis. They have demonstrated strong in-vivo efficacy in pulmonary, cardiac, and skin models. Their lead lung program is advancing toward a human trial by year end, supported by a platform enabling rapid expansion into additional high-value indications.
Versatope Therapeutics is a clinical-stage biotechnology company developing vaccines and therapeutics using a proprietary nanovesicle platform. Their lead program, VT-105, is a universal flu vaccine that has a clear path to inflection and exit. The company is now raising its first seed round of $6M for a Phase I clinical study. It is supported by over $20M in NIH funding to date, additional non-dilutive funding pending, a successful IND with FDA allowance, and nine global patents.
Innova NanoJet® Technologies Ltd. a UK/US commercial-stage deep technology company, is redefining air safety with NanoJet®—a patented, filter-less aerosol platform designed for active airborne pathogen management. Our first commercial product, AirSancta® CDa, delivers rapid, whole-room purification and disinfection using water-based nano-atomization, offering structural cost and performance advantages over HEPA systems. With NHS England procurement framework acceptance, validated lab results, and scalable manufacturing in place, we are accelerating global commercialization of a category-defining technology.
MVT Pharma is a late-clinical stage biotech with near-term value inflection points. Its pipeline features a best-in-class microbubble contrast agent for echocardiography that has completed phase II and a Department of Defense-funded nanobubble therapeutic, which offers a faster, less expensive FDA device pathway to the multi-billion-dollar myocardial infarction market.
Fusogenix PLV is a proprietary gene delivery platform that enables access to new tissues, indications, and development opportunities by solving genetic medicine's major delivery limitations.
Cycling Designs’ product, Cyclesight, provides a real-time view of rear-approaching vehicles, allowing cyclists to react and avoid danger. spend considerable money on safety but there are still too many accidents and deaths. Cyclists can’t avoid what they can’t see. Cycling Desings sold 50 beta units to provide proof of concept and are now going to market with a phone app to provide the increased functionality that cyclists prefer and gives them a significant competitive advantage.
Compact Medical Inc. is on track to capture a significant share of the US first-responder market with the ButterflyBVM™, and we are looking for partners to help us expand our launch and help prevent injuries from common CPR errors.
Biosartia Microbiomics invites investors to evaluate their lead oral weight-loss asset—a novel GLP-1R positive allosteric modulator (PAM) with selective polypharmacology —and to explore how their deep access and prediction engine can fill Pharma's pipelines with validated, nature-derived candidates that synthetic libraries simply cannot provide.
Pilot scale production of Omega Power Safe™ fireproof batteries will lead to a fast-track to revenue with their U.S. based manufacturing partnerships. Follow on Series A funding of $25M will lead to commercial scale production capacity to ramp up annual revenue to over $100M. This gives Omega Power a first-movers advantage in targeting the non-EV, power hungry AI robotics and drone markets, prioritizing safety, using their licensed and patented components and proprietary non-flammable electrolyte to supply these highly profitable, yet underserved market segments looking to transition to a “Made in America” cell supplier to avoid tariff and supply chain risks.